Klaria Pharma Holding AB (publ.) (STO:KLAR)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.7980
+0.0420 (5.56%)
Mar 25, 2026, 5:18 PM CET
Market Cap185.96M +2.4%
Revenue (ttm)8.99M +299.7%
Net Income-38.89M
EPS-0.21
Shares Out245.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume470,539
Average Volume377,206
Open0.7720
Previous Close0.7560
Day's Range0.7600 - 0.8000
52-Week Range0.3960 - 1.7000
Beta1.44
RSI43.12
Earnings DateFeb 20, 2026

About STO:KLAR

Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of... [Read more]

Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol KLAR
Full Company Profile

Financial Performance

In 2025, STO:KLAR's revenue was 8.99 million, an increase of 299.69% compared to the previous year's 2.25 million. Losses were -38.89 million, -18.56% less than in 2024.

Financial Statements